Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses (2016 - 2023)

Lineage Cell Therapeutics (LCTX) has 13 years of Other Accumulated Expenses data on record, last reported at $1000.0 in Q2 2023.

  • For Q2 2023, Other Accumulated Expenses fell 90.0% year-over-year to $1000.0; the TTM value through Jun 2023 reached $1000.0, down 90.0%, while the annual FY2020 figure was $9000.0, 125.0% up from the prior year.
  • Other Accumulated Expenses reached $1000.0 in Q2 2023 per LCTX's latest filing, down from $37000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $492000.0 in Q2 2021 and bottomed at $1000.0 in Q2 2023.
  • Average Other Accumulated Expenses over 5 years is $71533.3, with a median of $25000.0 recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: surged 1280.0% in 2021, then plummeted 97.97% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $4000.0 in 2019, then skyrocketed by 125.0% to $9000.0 in 2020, then soared by 666.67% to $69000.0 in 2021, then tumbled by 63.77% to $25000.0 in 2022, then plummeted by 96.0% to $1000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $1000.0 in Q2 2023, $37000.0 in Q1 2023, and $25000.0 in Q3 2022.